- Home
- OXBR vs BOLT Comparison
OXBR vs BOLT Comparison
Compare OXBR & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXBR | BOLT |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 10.5M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OXBR | BOLT |
|---|---|---|
| Price | $1.25 | $5.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $34.00 |
| AVG Volume (30 Days) | 12.0K | ★ 31.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,423,000.00 | ★ $5,195,000.00 |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $4.41 |
| 52 Week High | $5.81 | $12.60 |
Technical Indicators
Market Signals| Indicator | OXBR | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 49.12 |
| Support Level | $1.17 | $5.09 |
| Resistance Level | $1.30 | $5.71 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.23 | 23.48 |
Price Performance
Historical ComparisonAbout OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.